Literature DB >> 24778693

Ten years of experience in the prevention of mother-to-child human immunodeficiency virus transmission in a university teaching hospital.

Jung-Weon Park1, Tae-Whan Yang1, Yun-Kyung Kim1, Byung-Min Choi1, Hai-Joong Kim2, Dae-Won Park3.   

Abstract

PURPOSE: Administration of antiretroviral drugs to mothers and infants significantly decreases mother-to-child human immunodeficiency virus (HIV) transmission; cesarean sections and discouraging breastfeeding further decreases this risk. The present study confirmed the HIV status of babies born to mothers infected with HIV and describes the characteristics of babies and mothers who received preventive treatment.
METHODS: This study retrospectively analyzed medical records of nine infants and their mothers positive for HIV who gave birth at Korea University Ansan Hospital, between June 1, 2003, and May 31, 2013. Maternal parameters, including HIV diagnosis date, CD4+ count, and HIV ribonucleic acid (RNA) copy number, were analyzed. Infant growth and development, HIV RNA copy number, and HIV antigen/antibody test results were analyzed.
RESULTS: Eight HIV-positive mothers delivered nine babies; all the infants received antiretroviral therapy. Three (37.5%) and five mothers (62.5%) were administered single- and multidrug therapy, respectively. Intravenous zidovudine was administered to four infants (50%) at birth. Breastfeeding was discouraged for all the infants. All the infants were negative for HIV, although two were lost to follow-up. Third trimester maternal viral copy numbers were less than 1,000 copies/mL with a median CD4+ count of 325/µL (92-729/µL). Among the nine infants, two were preterm (22.2%) and three had low birth weights (33.3%).
CONCLUSION: This study concludes that prophylactic antiretroviral therapy, scheduled cesarean section, and prohibition of breastfeeding considerably decrease mother-to-child HIV transmission. Because the number of infants infected via mother-to-child transmission may be increasing, studies in additional regions using more variables are necessary.

Entities:  

Keywords:  Antiretroviral therapy; HIV infections; Postnatal care; Prevention of HIV infections; Vertical transmission of infectious disease

Year:  2014        PMID: 24778693      PMCID: PMC4000757          DOI: 10.3345/kjp.2014.57.3.117

Source DB:  PubMed          Journal:  Korean J Pediatr        ISSN: 1738-1061


  21 in total

1.  Trends in perinatal transmission of HIV/AIDS in the United States.

Authors:  M L Lindegren; R H Byers; P Thomas; S F Davis; B Caldwell; M Rogers; M Gwinn; J W Ward; P L Fleming
Journal:  JAMA       Date:  1999-08-11       Impact factor: 56.272

2.  Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study.

Authors:  S H Landesman; L A Kalish; D N Burns; H Minkoff; H E Fox; C Zorrilla; P Garcia; M G Fowler; L Mofenson; R Tuomala
Journal:  N Engl J Med       Date:  1996-06-20       Impact factor: 91.245

3.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  R S Sperling; D E Shapiro; R W Coombs; J A Todd; S A Herman; G D McSherry; M J O'Sullivan; R B Van Dyke; E Jimenez; C Rouzioux; P M Flynn; J L Sullivan
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

4.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Authors:  Ellen R Cooper; Manhattan Charurat; Lynne Mofenson; I Celine Hanson; Jane Pitt; Clemente Diaz; Karen Hayani; Edward Handelsman; Vincent Smeriglio; Rodney Hoff; William Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

5.  Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Authors:  P M Garcia; L A Kalish; J Pitt; H Minkoff; T C Quinn; S K Burchett; J Kornegay; B Jackson; J Moye; C Hanson; C Zorrilla; J F Lew
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

6.  Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial.

Authors: 
Journal:  Lancet       Date:  1999-03-27       Impact factor: 79.321

7.  Combination antiretroviral therapy and duration of pregnancy.

Authors: 
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

8.  Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe.

Authors:  Claire Thorne; Deven Patel; Marie-Louise Newell
Journal:  AIDS       Date:  2004-11-19       Impact factor: 4.177

9.  Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort.

Authors:  Béatrice Barret; Marc Tardieu; Pierre Rustin; Catherine Lacroix; Brigitte Chabrol; Isabelle Desguerre; Catherine Dollfus; Marie-Jeanne Mayaux; Stéphane Blanche
Journal:  AIDS       Date:  2003-08-15       Impact factor: 4.177

10.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

Authors:  J Brooks Jackson; Philippa Musoke; Thomas Fleming; Laura A Guay; Danstan Bagenda; Melissa Allen; Clemensia Nakabiito; Joseph Sherman; Paul Bakaki; Maxensia Owor; Constance Ducar; Martina Deseyve; Anthony Mwatha; Lynda Emel; Corey Duefield; Mark Mirochnick; Mary Glenn Fowler; Lynne Mofenson; Paolo Miotti; Maria Gigliotti; Dorothy Bray; Francis Mmiro
Journal:  Lancet       Date:  2003-09-13       Impact factor: 79.321

View more
  1 in total

1.  Pregnancy Rates and Outcomes of HIV-Infected Women in Korea.

Authors:  Heun Choi; Moo Hyun Kim; Se Ju Lee; Eun Jin Kim; Woonji Lee; Wooyong Jeong; In Young Jung; Jin Young Ahn; Su Jin Jeong; Nam Su Ku; Ji Hyeon Baek; Young Hwa Choi; Hyo Youl Kim; June Myung Kim; Jun Yong Choi
Journal:  J Korean Med Sci       Date:  2018-10-25       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.